Innovent and Lilly’s Halpryza (biosimilar, rituximab) Receive NMPA’s Approval in China

Shots:

• NMPA has approved Halpryza for patients with DLBCL, FL, and CLL in China. The biosimilar is the fourth mAb approved in China following the approval of Tyvyt (biosimilar, sintilimab), Byvasda (biosimilar, bevacizumab) and Sulinno (biosimilar, adalimumab)
• The clinical efficacy and safety of rituximab in CD20 +ve NHL have been confirmed in multiple large-scale clinical trials. Rituximab has received its FDA’s approval in 1997 for NHL, CLL, RA, GPA, MPA and PV
• The approval of Halpryza will bring a new option to Chinese Lymphoma patients, help them to improve QoL & prolong their survival. Halprryza is rituximab injection and a recombinant human/murine chimeric mAb targeting CD20 antigen on the surface of B lymphocytes and mediates CDC and ADCC
  
  Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: AASTOCKS